- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00957229
To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS) (GDC-0449)
December 16, 2020 updated by: UCSF Benioff Children's Hospital Oakland
A Randomized, Phase II Multicenter Trial Evaluating the Efficacy and Safety of a Systemic Hedgehog Pathway Antagonist (GDC-0449) in Patients With Basal Cell Nevus Syndrome (BCNS)
The purpose of this study is to reduce the number of new surgically eligible BCCs by 50% appearing during month 3-18 of medication ingestion.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a Phase II, 18 month, double blind, randomized placebo-controlled, two arm multicenter clinical study design.
During the 18-month treatment period, the safety and chemopreventive efficacy of 150 mg/day GDC-0449 versus placebo will be assessed, and include evaluations of the skin at monthly intervals for the first three months and then every 3 months for the next 15 months.
Removal of new surgically eligible BCCs (SEBs) will be done by primary skin care physicians (PSCPs) or at Study Centers.
A Data Safety Monitoring Board (DSMB) will review unblinded results for an interim analysis when 20 subjects have completed 12 months of drug.
This review will focus on adverse events and efficacy results.
Subjects will be monitored for the development of new SEBs after they discontinue study treatment.
At the end of the 18 months, given that the observed adverse events are minimal, patients on placebo will be offered the opportunity to take GDC-0449 for 18 months in an open label continuation, followed by six months observation, and patients on GDC449 will be monitored for the next 24 months for assessment of the duration of benefit after stopping the drug.
Study Type
Interventional
Enrollment (Actual)
41
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Oakland, California, United States, 94609
- Children's Hospital Oakland Research Institiute
-
-
New York
-
New York, New York, United States, 10032
- Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
The subject:
- has had diagnosed at least 10 SEB (of diameter 3 mm diameter or greater on the nose or periorbital skin, 5 mm or greater elsewhere on the face, or 9 mm or greater on non-facial areas excluding the skin below the knees) during the two years before study entry, as documented histologically in physicians' records and/or diagnosed clinically by a Study Investigator at baseline.
- meet diagnostic criteria for basal cell nevus syndrome
- is willing to abstain from application of non-study topical medications to the skin for the duration of the study, including prescription and over the counter preparations. Subjects will be encouraged to use sunscreen (SPF 15) at least once daily on all exposed skin sites.
- is willing to forego treatment of BCCs unless the BCCs are documented by Study Investigators, preferably on two separate visits, except when the PSCP believes that delay in treatment potentially might compromise the health of the subject.
- has normal laboratory tests as defined by the following: Normal hematopoietic capacity, Normal hepatic function: AST and ALT greater than or equal to 2x the upper limit of normal (ULN) Total bilirubin within normal range 0.20 mg/dl to 1.50 mg/dl or within 3x ULN for patients with Gilbert's disease Normal renal function: normal serum creatinine or measured creatinine clearance less than 50 mL/minute. Fasting cholesterol greater than or equal to 220 untreated
- be willing to not donate blood or semen for three months following discontinuation of Study medications.
- is willing to avoid pregnancy in his partner as defined by the following: Male subject is willing to use a latex condom during the study and for 3 months after the last dose during sexual contact with a female of childbearing potential, even if he has had a successful vasectomy. His partner must also use a form of birth control
Exclusion Criteria:
The subject:
- has used topical or systemic therapies that might interfere with the evaluation of the study medication during the study. Specifically these include the use of: (i) glucocorticoids to more than 5% of the skin (ii) retinoids systemically or topically to more than 5% of the skin during the six months prior to study entry; (iii) alpha-hydroxy acids to more than 5% of the skin during the six months prior to study entry (iv) 5-fluorouracil or imiquimod systemically or topically to the skin above the knees during the six months prior to study entry. (v) treatment with systemic chemotherapy within one year prior to starting study medication.
- has a history of hypersensitivity to any of the ingredients in the study medication formulations.
- is unable to return for follow-up visits and tests.
- has uncontrolled systemic disease, including known HIV positive patients.
- has history of congestive heart failure.
- has uncontrolled hypocalcemia, hypomagnesemia, or hypokalemia
- has clinically important history of liver disease, including viral or hepatitis, current alcohol abuse, or cirrhosis.
- has any condition or situation which in the Investigator's opinion may put the subject at significant risk, could confound the study results, or could interfere significantly with the subject's participation in the study.
- has a history of invasive cancer within the past five years excluding non-melanoma skin cancer, Stage I cervical cancer, ductal carcinoma in situ of the breast, or CLL Stage 0.
- has current, recent (within 4 weeks of Day 1), or planned participation in an experimental drug study while enrolled in this study.
- is a female who is pregnant, plans to ever to become pregnant, capable of becoming pregnant or is breast feeding.
- is a male who is unwilling or unable to comply with pregnancy prevention measures.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Sugar pill
placebo pill by mouth once daily
|
capsule, 150 mg, one pill daily, 18 months
Other Names:
|
Experimental: GDC-0449
vismodegib 150MG by mouth once daily
|
capsule, 150 mg, one pill daily, 18 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of New Surgically Eligible Basal-cell Carcinomas
Time Frame: 3 months of receiving study drug
|
Number of new surgically eligible basal-cell carcinomas per patient per year
|
3 months of receiving study drug
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Size of the Existing Carcinomas, Expressed as the Sum of Cumulative Diameters in Millimeters Over an 18 Month Period
Time Frame: Baseline and 18 months
|
Baseline and 18 months
|
|
Number of New Surgically Eligible Basal-cell Carcinomas After Stopping Vismodegib Treatment
Time Frame: These five patients were given placebo for a mean of 7.4 months (SD 2.3). After receiving vismodegib for a mean of 13.8 months (SD 6.8) and then discontinuing vismodegib for a mean of 11.8 months (SD 7.9) the new basal-cell carcinoma rate is reported.
|
The number of new surgically eligible basal-cell carcinomas per patient per month is reported.
|
These five patients were given placebo for a mean of 7.4 months (SD 2.3). After receiving vismodegib for a mean of 13.8 months (SD 6.8) and then discontinuing vismodegib for a mean of 11.8 months (SD 7.9) the new basal-cell carcinoma rate is reported.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J, Bickers DR, Epstein EH Jr. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012 Jun 7;366(23):2180-8. doi: 10.1056/NEJMoa1113538.
- Ally MS, Tang JY, Joseph T, Thompson B, Lindgren J, Raphael MA, Ulerio G, Chanana AM, Mackay-Wiggan JM, Bickers DR, Epstein EH Jr. The use of vismodegib to shrink keratocystic odontogenic tumors in patients with basal cell nevus syndrome. JAMA Dermatol. 2014 May;150(5):542-5. doi: 10.1001/jamadermatol.2013.7444.
- Tang JY, Ally MS, Chanana AM, Mackay-Wiggan JM, Aszterbaum M, Lindgren JA, Ulerio G, Rezaee MR, Gildengorin G, Marji J, Clark C, Bickers DR, Epstein EH Jr. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016 Dec;17(12):1720-1731. doi: 10.1016/S1470-2045(16)30566-6. Epub 2016 Nov 10.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2009
Primary Completion (Actual)
January 1, 2014
Study Completion (Actual)
January 1, 2014
Study Registration Dates
First Submitted
August 5, 2009
First Submitted That Met QC Criteria
August 11, 2009
First Posted (Estimate)
August 12, 2009
Study Record Updates
Last Update Posted (Actual)
January 11, 2021
Last Update Submitted That Met QC Criteria
December 16, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Disease
- Cysts
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Musculoskeletal Diseases
- Stomatognathic Diseases
- Bone Diseases
- Neoplastic Syndromes, Hereditary
- Nevi and Melanomas
- Jaw Diseases
- Abnormalities, Multiple
- Bone Diseases, Developmental
- Odontogenic Cysts
- Jaw Cysts
- Bone Cysts
- Carcinoma, Basal Cell
- Neoplasms, Basal Cell
- Syndrome
- Nevus
- Basal Cell Nevus Syndrome
- Nevus, Pigmented
Other Study ID Numbers
- 2009-026
- SHH-4685s (Other Grant/Funding Number: Genentech)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Basal Cell Nevus Syndrome
-
Ascend Biopharmaceuticals LtdSuspendedBasal Cell Carcinoma in Basal Cell Nevus SyndromeUnited States
-
PellePharm, Inc.CompletedBasal Cell Nevus SyndromeUnited States, Spain, Germany, United Kingdom, Italy, France, Belgium, Canada, Denmark, Netherlands
-
HedgePath Pharmaceuticals, Inc.CompletedBasal Cell Carcinoma in Basal Cell Nevus SyndromeUnited States
-
Sol-Gel Technologies, Ltd.TerminatedBasal Cell Nevus SyndromeUnited States, France, Belgium, Denmark, Germany, Italy, Netherlands, Spain, United Kingdom
-
Edward Maytin, MD, PhDDUSA Pharmaceuticals, Inc.CompletedBasal Cell Nevus SyndromeUnited States
-
Columbia UniversityWithdrawnBasal Cell Nevus Syndrome
-
University Health Network, TorontoCompletedBasal Cell Nevus SyndromeCanada
-
MelanomaPRO, RussiaPrivolzhsky Research Medical UniversityRecruitingNevus | Nevus, Pigmented | Melanoma (Skin) | Basal Cell Carcinoma | Squamous Cell Carcinoma | Bowen's Disease | Nevus, Spitz | Melanoma in Situ | Nevus Halo | Spot PigmentedRussian Federation
-
QLT Inc.NovartisTerminatedNevoid Basal Cell Carcinoma Syndrome | Basal Cell Carcinoma | Gorlin Syndrome
-
Massachusetts General HospitalCompletedBasal Cell Carcinoma | Squamous Cell Carcinoma | Atypical NevusUnited States
Clinical Trials on GDC-0449
-
Stanford UniversityNational Cancer Institute (NCI); University Hospitals Cleveland Medical CenterCompletedRecurrent Skin Cancer | Basal Cell Carcinoma of the SkinUnited States
-
National Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)CompletedAdult MedulloblastomaUnited States
-
National Cancer Institute (NCI)Genentech, Inc.TerminatedChronic Graft Versus Host DiseaseUnited States
-
Genentech, Inc.Completed
-
Lisa BaxRoche Pharma AG; Genentech, Inc.TerminatedPancreatic Ductal AdenocarcinomaUnited Kingdom
-
Genentech, Inc.CompletedA Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell CarcinomaBasal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood MedulloblastomaUnited States
-
Genentech, Inc.Approved for marketingBasal Cell CarcinomaUnited States